Healthcare cost by primary tumour, functioning status and treatment among patients with metastatic neuroendocrine tumours: The LyREMeNET study
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Neuroendocrinology"
DOI: 10.1111/jne.13092
Abstract: The annual prevalence of metastatic neuroendocrine tumours (mNETs) is rising, leading to significant healthcare costs. The present study aimed to describe healthcare resource use (HRU) and the corresponding costs among patients with mNETs, according to… read more here.
Keywords: pppm; mnet; cost; study ... See more keywords